Margaret Lee Gourlay1, Robert A Overman, Jason P Fine, Kristine E Ensrud, Carolyn J Crandall, Margery L Gass, John Robbins, Karen C Johnson, Erin S LeBlanc, Catherine R Womack, John T Schousboe, Andrea Z LaCroix. 1. From the 1Department of Family Medicine, University of North Carolina, Chapel Hill, NC; 2Division of Pharmaceutical Outcomes and Policy, Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC; 3Department of Biostatistics, University of North Carolina, Chapel Hill, NC; 4Department of Medicine, VA Medical Center, Minneapolis, MN; 5Department of Medicine, University of California Los Angeles, Los Angeles, CA; 6The North American Menopause Society, Mayfield Heights, OH; 7University of California at Davis, Sacramento, CA; 8University of Tennessee Health Science Center, Memphis, TN; 9Center for Health Research, Kaiser Permanente Northwest, Portland, OR;10Division of Health Policy and Management, University of Minnesota, Minneapolis, MN; and 11Fred Hutchinson Cancer Research Center, Seattle, WA.
Abstract
OBJECTIVE: This study aims to estimate the incidence of first hip or clinical vertebral fracture or major osteoporotic (hip, clinical vertebral, proximal humerus, or wrist) fracture in postmenopausal women undergoing their first bone mineral density (BMD) test before age 65 years. METHODS: We studied 4,068 postmenopausal women, aged 50 to 64 years without hip or clinical vertebral fracture or antifracture treatment at baseline, who were participating in the Women's Health Initiative BMD cohort study. BMD tests were performed between October 1993 and April 2005, with fracture follow-up through 2012. Outcomes were the time for 1% of women to sustain a hip or clinical vertebral fracture and the time for 3% of women to sustain a major osteoporotic fracture before initiating treatment, adjusting for clinical risk factors and accounting for competing risks. Women without osteoporosis and women with osteoporosis on their first BMD test were analyzed separately. RESULTS: During a maximum of 11.2 years of concurrent BMD and fracture follow-up, the adjusted estimated time for 1% of women to have a hip or clinical vertebral fracture was 12.8 years (95% CI, 8.0-20.4) for women aged 50 to 54 years without baseline osteoporosis, 7.6 years (95% CI, 4.8-12.1) for women aged 60 to 64 years without baseline osteoporosis, and 3.0 years (95% CI, 1.3-7.1) for all women aged 50 to 64 years with baseline osteoporosis. Results for major osteoporotic fracture were similar. CONCLUSIONS: Because of very low rates of major osteoporotic fracture, postmenopausal women aged 50 to 64 years without osteoporosis on their first BMD test are unlikely to benefit from frequent rescreening before age 65 years.
OBJECTIVE: This study aims to estimate the incidence of first hip or clinical vertebral fracture or major osteoporotic (hip, clinical vertebral, proximal humerus, or wrist) fracture in postmenopausal women undergoing their first bone mineral density (BMD) test before age 65 years. METHODS: We studied 4,068 postmenopausal women, aged 50 to 64 years without hip or clinical vertebral fracture or antifracture treatment at baseline, who were participating in the Women's Health Initiative BMD cohort study. BMD tests were performed between October 1993 and April 2005, with fracture follow-up through 2012. Outcomes were the time for 1% of women to sustain a hip or clinical vertebral fracture and the time for 3% of women to sustain a major osteoporotic fracture before initiating treatment, adjusting for clinical risk factors and accounting for competing risks. Women without osteoporosis and women with osteoporosis on their first BMD test were analyzed separately. RESULTS: During a maximum of 11.2 years of concurrent BMD and fracture follow-up, the adjusted estimated time for 1% of women to have a hip or clinical vertebral fracture was 12.8 years (95% CI, 8.0-20.4) for women aged 50 to 54 years without baseline osteoporosis, 7.6 years (95% CI, 4.8-12.1) for women aged 60 to 64 years without baseline osteoporosis, and 3.0 years (95% CI, 1.3-7.1) for all women aged 50 to 64 years with baseline osteoporosis. Results for major osteoporotic fracture were similar. CONCLUSIONS: Because of very low rates of major osteoporotic fracture, postmenopausal women aged 50 to 64 years without osteoporosis on their first BMD test are unlikely to benefit from frequent rescreening before age 65 years.
Authors: E S Siris; S K Brenneman; E Barrett-Connor; P D Miller; S Sajjan; M L Berger; Y-T Chen Journal: Osteoporos Int Date: 2006-01-04 Impact factor: 4.507
Authors: Ethel S Siris; Ya-Ting Chen; Thomas A Abbott; Elizabeth Barrett-Connor; Paul D Miller; Lois E Wehren; Marc L Berger Journal: Arch Intern Med Date: 2004-05-24
Authors: Jeffrey R Curtis; Laura Carbone; Hong Cheng; Burton Hayes; Andrew Laster; Robert Matthews; Kenneth G Saag; Robert Sepanski; Simpson B Tanner; Elizabeth Delzell Journal: J Bone Miner Res Date: 2008-07 Impact factor: 6.741
Authors: A C Looker; C C Johnston; H W Wahner; W L Dunn; M S Calvo; T B Harris; S P Heyse; R L Lindsay Journal: J Bone Miner Res Date: 1995-05 Impact factor: 6.741
Authors: Margaret L Gourlay; Robert A Overman; Jason P Fine; Carolyn J Crandall; John Robbins; John T Schousboe; Kristine E Ensrud; Erin S LeBlanc; Margery L Gass; Karen C Johnson; Catherine R Womack; Andrea Z LaCroix Journal: Am J Med Date: 2017-03-09 Impact factor: 4.965
Authors: Margaret L Gourlay; Robert A Overman; Jason P Fine; Guillaume Filteau; Peggy M Cawthon; John T Schousboe; Eric S Orwoll; Timothy J Wilt; Tuan V Nguyen; Nancy E Lane; Pawel Szulc; Brent C Taylor; Thuy-Tien Dam; Carrie M Nielson; Jane A Cauley; Elizabeth Barrett-Connor; Howard A Fink; Jodi A Lapidus; Deborah M Kado; Susan J Diem; Kristine E Ensrud Journal: Am J Prev Med Date: 2016-01-25 Impact factor: 5.043